Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Thomas A. Lagace, David E. Curtis, Rita Garuti, Markey C. McNutt, Wook Park Sahng, Heidi B. Prather, Norma N. Anderson, Y. K. Ho, Robert E Hammer, Jay D Horton

Research output: Contribution to journalArticle

402 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of subtilases that reduces the number of LDL receptors (LDLRs) in liver through an undefined posttranscriptional mechanism. We show that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner. This activity was approximately 10-fold greater for a gain-of-function mutant, PCSK9(D374Y), that causes hypercholesterolemia. Binding and uptake of PCSK9 were largely dependent on the presence of LDLRs. Coimmunoprecipitation and ligand blotting studies indicated that PCSK9 and LDLR directly associate; both proteins colocalized to late endocytic compartments. Purified PCSK9 had no effect on cell-surface LDLRs in hepatocytes lacking autosomal recessive hypercholesterolemia (ARH), an adaptor protein required for endocytosis of the receptor. Transgenic mice overexpressing human PCSK9 in liver secreted large amounts of the protein into plasma, which increased plasma LDL cholesterol concentrations to levels similar to those of LDLR-knockout mice. To determine whether PCSK9 was active in plasma, transgenic PCSK9 mice were parabiosed with wild-type littermates. After parabiosis, secreted PCSK9 was transferred to the circulation of wild-type mice and reduced the number of hepatic LDLRs to nearly undetectable levels. We conclude that secreted PCSK9 associates with the LDLR and reduces hepatic LDLR protein levels.

Original languageEnglish (US)
Pages (from-to)2995-3005
Number of pages11
JournalJournal of Clinical Investigation
Volume116
Issue number11
DOIs
StatePublished - Nov 1 2006

Fingerprint

LDL Receptors
Hepatocytes
Liver
Cell Surface Receptors
Parabiosis
low density lipoprotein inhibitor
Proprotein Convertase 9
Endopeptidase K
Proteins
Hep G2 Cells
Endocytosis
Hypercholesterolemia
Knockout Mice
LDL Cholesterol
Transgenic Mice
Blood Proteins
Cell Count
Ligands

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. / Lagace, Thomas A.; Curtis, David E.; Garuti, Rita; McNutt, Markey C.; Sahng, Wook Park; Prather, Heidi B.; Anderson, Norma N.; Ho, Y. K.; Hammer, Robert E; Horton, Jay D.

In: Journal of Clinical Investigation, Vol. 116, No. 11, 01.11.2006, p. 2995-3005.

Research output: Contribution to journalArticle

Lagace, TA, Curtis, DE, Garuti, R, McNutt, MC, Sahng, WP, Prather, HB, Anderson, NN, Ho, YK, Hammer, RE & Horton, JD 2006, 'Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice', Journal of Clinical Investigation, vol. 116, no. 11, pp. 2995-3005. https://doi.org/10.1172/JCI29383
Lagace, Thomas A. ; Curtis, David E. ; Garuti, Rita ; McNutt, Markey C. ; Sahng, Wook Park ; Prather, Heidi B. ; Anderson, Norma N. ; Ho, Y. K. ; Hammer, Robert E ; Horton, Jay D. / Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. In: Journal of Clinical Investigation. 2006 ; Vol. 116, No. 11. pp. 2995-3005.
@article{524493cc1d1d484e89d5e513b744d576,
title = "Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice",
abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of subtilases that reduces the number of LDL receptors (LDLRs) in liver through an undefined posttranscriptional mechanism. We show that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner. This activity was approximately 10-fold greater for a gain-of-function mutant, PCSK9(D374Y), that causes hypercholesterolemia. Binding and uptake of PCSK9 were largely dependent on the presence of LDLRs. Coimmunoprecipitation and ligand blotting studies indicated that PCSK9 and LDLR directly associate; both proteins colocalized to late endocytic compartments. Purified PCSK9 had no effect on cell-surface LDLRs in hepatocytes lacking autosomal recessive hypercholesterolemia (ARH), an adaptor protein required for endocytosis of the receptor. Transgenic mice overexpressing human PCSK9 in liver secreted large amounts of the protein into plasma, which increased plasma LDL cholesterol concentrations to levels similar to those of LDLR-knockout mice. To determine whether PCSK9 was active in plasma, transgenic PCSK9 mice were parabiosed with wild-type littermates. After parabiosis, secreted PCSK9 was transferred to the circulation of wild-type mice and reduced the number of hepatic LDLRs to nearly undetectable levels. We conclude that secreted PCSK9 associates with the LDLR and reduces hepatic LDLR protein levels.",
author = "Lagace, {Thomas A.} and Curtis, {David E.} and Rita Garuti and McNutt, {Markey C.} and Sahng, {Wook Park} and Prather, {Heidi B.} and Anderson, {Norma N.} and Ho, {Y. K.} and Hammer, {Robert E} and Horton, {Jay D}",
year = "2006",
month = "11",
day = "1",
doi = "10.1172/JCI29383",
language = "English (US)",
volume = "116",
pages = "2995--3005",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

AU - Lagace, Thomas A.

AU - Curtis, David E.

AU - Garuti, Rita

AU - McNutt, Markey C.

AU - Sahng, Wook Park

AU - Prather, Heidi B.

AU - Anderson, Norma N.

AU - Ho, Y. K.

AU - Hammer, Robert E

AU - Horton, Jay D

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of subtilases that reduces the number of LDL receptors (LDLRs) in liver through an undefined posttranscriptional mechanism. We show that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner. This activity was approximately 10-fold greater for a gain-of-function mutant, PCSK9(D374Y), that causes hypercholesterolemia. Binding and uptake of PCSK9 were largely dependent on the presence of LDLRs. Coimmunoprecipitation and ligand blotting studies indicated that PCSK9 and LDLR directly associate; both proteins colocalized to late endocytic compartments. Purified PCSK9 had no effect on cell-surface LDLRs in hepatocytes lacking autosomal recessive hypercholesterolemia (ARH), an adaptor protein required for endocytosis of the receptor. Transgenic mice overexpressing human PCSK9 in liver secreted large amounts of the protein into plasma, which increased plasma LDL cholesterol concentrations to levels similar to those of LDLR-knockout mice. To determine whether PCSK9 was active in plasma, transgenic PCSK9 mice were parabiosed with wild-type littermates. After parabiosis, secreted PCSK9 was transferred to the circulation of wild-type mice and reduced the number of hepatic LDLRs to nearly undetectable levels. We conclude that secreted PCSK9 associates with the LDLR and reduces hepatic LDLR protein levels.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of subtilases that reduces the number of LDL receptors (LDLRs) in liver through an undefined posttranscriptional mechanism. We show that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner. This activity was approximately 10-fold greater for a gain-of-function mutant, PCSK9(D374Y), that causes hypercholesterolemia. Binding and uptake of PCSK9 were largely dependent on the presence of LDLRs. Coimmunoprecipitation and ligand blotting studies indicated that PCSK9 and LDLR directly associate; both proteins colocalized to late endocytic compartments. Purified PCSK9 had no effect on cell-surface LDLRs in hepatocytes lacking autosomal recessive hypercholesterolemia (ARH), an adaptor protein required for endocytosis of the receptor. Transgenic mice overexpressing human PCSK9 in liver secreted large amounts of the protein into plasma, which increased plasma LDL cholesterol concentrations to levels similar to those of LDLR-knockout mice. To determine whether PCSK9 was active in plasma, transgenic PCSK9 mice were parabiosed with wild-type littermates. After parabiosis, secreted PCSK9 was transferred to the circulation of wild-type mice and reduced the number of hepatic LDLRs to nearly undetectable levels. We conclude that secreted PCSK9 associates with the LDLR and reduces hepatic LDLR protein levels.

UR - http://www.scopus.com/inward/record.url?scp=33750597734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750597734&partnerID=8YFLogxK

U2 - 10.1172/JCI29383

DO - 10.1172/JCI29383

M3 - Article

C2 - 17080197

AN - SCOPUS:33750597734

VL - 116

SP - 2995

EP - 3005

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -